C-Path’s Role as a Neutral Convener

Critical Path Institute (C-Path) serves as a Neutral Convener, bringing together regulatory, industry, academia, and patient stakeholders to address challenges in getting safe and effective therapies to patients in areas of unmet medical need. The legal and contractual framework in which stakeholders are convened and governed may vary depending on the scientific objectives, funding, and stakeholder alignment. C-Path operates mainly through public-private partnerships that work on multi-stakeholder projects funded by consortia membership fees, government grants and contracts, foundations, and other donors. For C-Path to maintain its role as Neutral Convener, it must maintain practices to avoid perceived or actual conflicts of interest. Management of perceived or actual conflicts by and between C-Path board directors, employees, and partners are outlined in C-Path’s Institutional Conflict of Interest Policy.

C-Path leads collaborations that accelerate drug development, advancing better treatments for people worldwide.